CLINICAL_TRIALS
trial_result
· 2017-06-29
Clinical Trial Update: CNDO-109-AANK for AML in First Complete Remission (CR1) [Phase 1, Phase 2]
Summary
This clinical trial update covers CNDO-109-AANK for acute myeloid leukemia in first complete remission (CR1) in Phase 1/Phase 2, with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Coronado Biosciences, Inc. | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: UNKNOWN | Results posted: 2017-06-29